

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-37. (Canceled)

38. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a ~~*H. pylori* cytotoxin~~ polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a fragment of the amino acid sequence of SEQ ID NO:3, which polypeptide: (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits substantially no toxicity, or substantially reduced ~~contribution to~~ toxicity.

39-43. (Canceled)

44. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a recombinantly produced ~~*H. pylori* cytotoxin~~ polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a fragment of an the amino acid sequence of SEQ ID NO:3, wherein said recombinantly produced polypeptide (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits substantially no toxicity, or substantially reduced ~~contribution to~~ toxicity, and a pharmaceutically acceptable carrier.

45. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a ~~*H. pylori* cytotoxin~~ polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a fragment of the amino acid sequence of SEQ ID NO:3, which polypeptide: (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits substantially no toxicity, or substantially reduced toxicity, and a pharmaceutically acceptable carrier.

46. (Currently amended) An immunogenic composition comprising an immunologically effective amount of a recombinantly produced *H. pylori* cytotoxin polypeptide comprising the amino acid sequence of SEQ ID NO:3, or a fragment of an the amino acid sequence of SEQ ID NO:3, wherein said recombinantly produced polypeptide (i) is immunologically identifiable by an antibody that reacts specifically with *H. pylori* cytotoxin and (ii) exhibits substantially no toxicity, or substantially reduced ~~contribution to~~ toxicity.